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Abstract
Background: More than 50% of hepatitis C viruses (HCV)-infected patients do not respond to the classical Interferon 
(IFN)/Ribavirin (RBV) combination therapy. The aim of this study was to evaluate the efficacy of retreatment with Peg-
Interferon alpha-2b (PEG-IFN alpha-2b) plus RBV, in patients with HCV, genotypes 1 or 3, who were non-responders to 
the previous standard treatment with IFN/RBV.
Methods: In the period 2005-2007, a total of 238 HCV chronic patients were non-responders to previous treatment 
with IFN plus RBV. Of these 130 agreed to be retreated with PEG-IFN alpha-2b and participated in this evaluation (90 
with genotype 1 HCV and 40 with genotype 3 HCV). Patients were retreated at assisted IFN application hubs in 
compliance with the country's public health system rules. They received subcutaneous PEG-IFN alpha-2b, 1.5 μg, once 
weekly, associated with RBV, through the oral route, with doses determined according to weight (1,000 mg if weight ≤ 
75 kg and 1,250 mg if > 75 kg). Patients with genotype 1 HCV were retreated for over 48 weeks and patients with 
genotype 3 HCV for over 24 weeks. HCV-RNA was tested by polymerase chain reaction (PCR) at baseline, at week 12, at 
the end of the treatment, and 6 months thereafter. The predictiveness of week 12 in the development of a sustained 
virologic response (SVR) was also evaluated. Patients with negative HCV-RNA at week 12 were considered as early 
virologic responders (EVR).
Results: EVR was observed in 25% of the patients with genotype 1 HCV and in 64% of the patients genotype 3 HCV 
(risk = 2.075 and p-value = 0.0414). SVR was observed in 22.2% of the patients with genotype 1 HCV and in 40% with 
genotype 3 HCV (intention-to-treat analysis). The positive predictive value (PPV) of the HCV-RNA testing at week 12, in 
order to obtain the SVR, was 65% for genotype 1 and 56% for genotype 3, and the negative predictive value (NPV) was 
88% for genotype 1 and 89% for genotype 3.
Conclusions: PEG-IFN alpha-2b plus weight-based ribavirin is effective in re-treating previous interferon-α plus RBV 
failure; 22.2% of the patients with genotype 1 HCV and 40% of patients with genotype 3 HCV achieved SVR.
Background
Initially the treatment of chronic hepatitis C (CHC) was
carried out with the combination of conventional alpha-
interferon (IFN-α) plus ribavirin (RBV) over 24-48 weeks
according to the genotype. Progressively, IFN-α was
replaced by pegylated interferon (PEG-IFN), because this
was the most efficacy regime [1-3]. The primary objective
of the treatment is to achieve undetectable HCV-RNA
with the polymerase chain reaction (PCR). During ther-
apy, this assay allows testing for the early virologic
response (EVR) at week 12, the end of treatment virologic
response (ETVR) and the sustained virologic response
(SVR) at 24 weeks after therapy suspension. In large
international multicentric studies, treatment-naive
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patients receiving PEG-IFN plus RBV showed 54-63% of
SVR when considering all viral genotypes [1-3]. The
treatment-naive patients infected by genotype 1 showed
lower SVR rates (42-46%), as compared with those
infected by genotypes 2 and 3 (76-82%). Some authors
who re-treated patients without SVR with combined
treatment of IFN-α plus RBV reported that it was better
to retreat relapsing patients than non-responders to the
previous treatment [4-9]. Authors also observed that
patients who were non-responders to monotherapy or
combined therapy of IFN-α plus RBV respond better than
non-responders to PEG-IFN plus RBV [5,8,10].
In Brazil, the public health system (SUS) provides free
drugs for the treatment of hepatitis C virus chronic
patients, in compliance with a specific Ministry of Health
protocol. This protocol determines that PEG-IFN is
administered weekly at reference centers called "applica-
tion hubs" which are outpatient departments. Under this
system it is estimated that the patients fully comply with
the treatment.
The primary objective of this study was to evaluate the
efficacy of retreating Brazilian patients with CHC, geno-
types 1 or 3, with PEG-IFN α-2b associated with RBV at a
public health system university hospital. These patients
were non-responders to previous conventional treatment.
The secondary objective was to evaluate the early viro-
logic response (EVR), characterized by the negativation
of HCV on week 12 and its SVR predictive value.
Methods
This was a retrospective study carried out by the Hepati-
tis Study Group from the Medical Sciences School at the
State University of Campinas (GEHEP). In the period
2005-2007, a total of 238 HCV non-responder patients to
previous treatment with interferon plus ribavirin were
considered for retreatment with PEG-IFN plus RBV. Of
this total, 172 had been treated at our institution of which
152 agreed to receive retreatment with PEG-IFN plus
RBV. Of these, 130 met the inclusion criteria and were
retreated, in compliance with the rules created by the
State of São Paulo Health Secretary and the Brazilian
Ministry of Health, which provided the medication. This
study was approved by our Ethical Committee. The eval-
uation included male and female patients, over 18, chron-
ically infected by hepatitis C virus (HCV) genotypes 1 or
3, who were non-responders to the previous treatment
with IFN-α plus RBV . Data were collected on age, sex,
ethnic group, alcohol abuse and the possible infection
route. Patients were considered as potentially contami-
nated through the parenteral route when they reported
receiving transfusions, injections with non-disposable
syringes or needles, or sharing materials used for mani-
cures, acupuncture or application of tattoos given in less
than optimal conditions. Patients were considered as
intravenous drug users (IVDU) when reporting the use of
illegal drugs or stimulants (Glucoenergan®) through the
intravenous route, in groups, and sharing syringes or nee-
dles.
At baseline, all patients showed positive serum test for
HCV-RNA by polymerase chain reaction (PCR-Cobas
Amplicor® HCV Test - Roche Molecular Systems Inc.). All
patients were negative for HBsAg and anti-HIV.
The previous treatment for HCV was carried out with
IFN-α 2a or 2b (3,000,000 UI, subcutaneous, three times a
week) plus RBV (administered through oral route, twice a
day, weight-based dose: 1,000 mg/day for patients under
75 kg and 1,250 mg/day for those weighing over 75 kg. In
Brazil this drug is provided free by the Ministry of Health
in capsules of 250 mg. All patients were treated at outpa-
tients departments. Patients with genotype 1 had been
treated for over 48 weeks and those with genotype 3 were
treated for over 24 weeks. Therapy was discontinued for
all patients infected with genotype 1 who had positive
HCV-RNA (PCR qualitative, PCR Amplicor HCV test -
Roche molecular systems) at week 24. So, only non-
responder patients (positive HCV-RNA at week 24) were
screened for this study. Patients relapsing or who had a
breakthrough in the first treatment were excluded. We
included in our sample only patients who had attended
every clinical evaluation of the first treatment, who had
received all the drugs from the hospital pharmacy and
had done all the biochemical and molecular tests
requested.
Before starting the retreatment, all patients had hemo-
globin > 10 g/dL, neutrophils > 1,500 cells/mm3, platelet
> 70,000/mm3, albumin > 3.5 mg/dL and INR < 1.2. The
bilirubin and creatinine levels were within normal values.
All patients had a liver biopsy performed no more than 18
months before the start of the study, and the diagnosis
was consistent with HCV. The inflammatory activity and
the fibrosis grade were evaluated by the Metavir score.
Patients were considered as carriers of non significant
fibrosis when classified as F0, F1 and F2. Patients with F3
and F4 were considered as significant fibrosis carriers.
Patients on hemodialysis, and heavy drug and alcohol
users unable to comply with the treatment, were
excluded. Other patients excluded had auto-immune,
degenerative, renal and hematological diseases, or had
other liver metabolic diseases, or those who had hyper-
sensitivity reaction or other contraindications to the
PEG-IFN plus RBV combination.
All patients were retreated with PEG-IFN α-2b associ-
ated with RBV. PEG-IFN α-2b was administered through
the subcutaneous route, with a once weekly dose of 1.5
μg. All doses were administered at reference centers
called "application hubs" which are outpatient depart-
ments. The 250 mg tablets of RBV were administered
through the oral route, twice a day, with the dose varyingGonçales et al. BMC Infectious Diseases 2010, 10:212
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according to the weight: 1,000 mg/day if the weight was
less than 75 kilos and 1,250 mg/day if the weight was over
75 kilos. The retreatment period for genotype 1 was 48
weeks, while for genotype 3 it was 24 weeks.
Clinical and biochemical evaluations were performed
before starting the treatment and then monthly through-
out the treatment (hemogram, AST, ALT, gama-GT, TSH
and free T4 dosing) in order to evaluate adverse events,
tolerance and efficacy. The AST, ALT and gamma-GT
levels were expressed in quotients (qALT, qAST, qGama-
GT). Thus, for example, the qALT was obtained by divid-
ing the serum ALT value by the method's highest normal
value. Those with qALT > 1 had increased ALT. In the
case of patients having severe adverse events or biochem-
ical abnormalities the dose of ribavirin or PEG-IFN α-2b
was reduced. In patients with hemoglobin levels lower
than 8.5 mg/dL, ribavirin was suspended and when the
hemoglobin levels varied between 8.5 and 10 mg/dL, the
dose was reduced to half of the initial. The reduction of
PEG-IFN α-2b to two-thirds of the initial dose occurred
when the platelet count was lower than 30,000/mm3 or
when the granulocyte count was lower than 750 cells/
mm3.
The HCV-RNA was detected by PCR at weeks 12, 24
and 48 for patients infected by genotype 1 and at weeks
12 and 24 for patients infected by genotype 3. The EVR
was tested at week 12 by qualitative HCV -RNA (PCR -
Cobas Amplicor® HCV Test version 2.0-Roche Molecular
Systems Inc.) in 104 patients, 78 (75%) with genotype 1
and 26 (25%) with genotype 3. Patients with negative PCR
on this occasion were considered as complete early viro-
logic responders (EVR). The end-of-treatment virologic
response (ETVR) was tested at week 24 (genotype 3) or
week 48 (genotype 1) by the same qualitative HCV-RNA
test. The SVR was evaluated by a HCV-RNA test at 24
weeks after the end of the treatment.
The patients' descriptive data analysis was presented in
tables for categorical variables. In order to identify risk
factors for the treatment responses, uni - and multivari-
ate Cox regression analyses were used. The adopted sig-
nificance level was 5%. The computer program SAS,
System for Windows (Statistical Analysis System), and
version 9.1.3 Service Pack 3, SAS Institute Inc, 2002-
2003, Cary, NC, USA was used.
Results
The evaluation included 130 patients with chronic hepa-
titis C who were non-responders to previous treatment
with IFN plus RBV, carried out at our outpatient depart-
ments. The main demographic, epidemiological and bio-
chemical data of the 130 patients are presented in Table 1.
Most of the patients were males (72%) and white (90%),
and the median age was 48. Around 33% of the patients
acquired the infection through the parenteral route, 21%
were IVDU and in 40% of the cases the acquisition route
of HCV was unknown. Alcohol abuse was present in 17%
of the studied population. Of the 130 patients, 90 (70%)
were infected by genotype 1 and 40 (30%) were infected
b y  g e n o t y p e  3 .  O n l y  1  ( 0 . 8 % )  o f  t h e  i n f e c t e d  p a t i e n t s
showed no fibrosis according to the Metavir score (F0);
19 (14.6%) were F1, 58 (44.6%) were F2, 38 (29.2%) were
F3, and 14 (10.8%) were F4. The groups, analyzed accord-
ing to the genotypes, showed similar characteristics,
demonstrating that no considerable bias occurred during
the data statistical analysis. A small difference, however,
was observed in the presence of significant fibrosis (F3
plus F4) in genotype 3 (45% of the patients against 37.8%
of genotype 1). Most patients (56%) did not need a reduc-
tion in their PEG-IFN or RBV doses.
Eleven out of 130 (8.5%) patients did not conclude the
treatment due to side effects resulting from the drugs
administered. These 11 patients were infected by HCV
genotype 1.Of the 90 patients with genotype 1, 79 (87.7%)
performed HCV-RNA testing (PCR) at week 12, while 25
(63%) of 40 patients infected by genotype 3 were also
tested in the same week. All of them completed the treat-
ment period and were tested for the presence of HCV-
RNA six months after the end of the therapy to estimate
the SVR rates. A higher percentage of patients with geno-
type 3 reached EVR (64%), when compared to genotype 1
(25%) (Figure 1).There were no significant differences in
the EVR of patients infected by genotypes 1 or 3, when
they were analyzed according to sex, race, mean age, alco-
hol abuse, and the kind of exposure or enzyme alterations
of AST , AL T and gamma-GT (T able 2). In both patient
groups there were no statistical differences in regard to
higher or lower EVR percentages associated with the liver
fibrosis grade.
By intention-to-treat (ITT) analysis the SVR was lower
in patients with genotype 1(20/90,22.2%) when compared
to 40% (16/40) of SVR in patients infected by genotype 3.
By per protocol analysis (PPA) the SVR also was lower in
patients infected by genotype 3 (20/79, 25.3%) compared
to 40% (16/40) of SVR in patients infected by genotype 3.
Figure 1 shows the results of the HCV-RNA testing at
week 12 (EVR) in the 104 patients who performed this
test and at 24 weeks after the end of the treatment. There
was a statistically significant correlation for both geno-
types concerning the absence of EVR and the absence of
SVR (NPV = Negative Predictive Value). The positive
predictive value (PPV) was 65% (13/20) for genotype 1
and 56% (9/16) for genotype 3 and the negative predictive
value (NPV) was 88% (52/59) and 89% (8/9), respectively.
It is important to note that 7 patients with genotype 1 and
only 1 with genotype 3 reached SVR, despite presenting
no EVR. In an unvaried Cox regression analysis, the sole
risk factor for not obtaining EVR was the presence of
infection by the genotype 1, with a risk of 2.075 (CI 95%Gonçales et al. BMC Infectious Diseases 2010, 10:212
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[1.029; 4.183]) and p value below 5% (0.0414). Regarding
the reduction of medication dosage, there was no statisti-
cally significant change in the SVR, with the reduction of
peg-interferon or ribavirin or both. Additionally, no rela-
tion was found between the fibrosis grade and lower
response to the treatment. The body mass index (BMI)
was also related to EVR and SVR for each genotype, with
no statistical differences between the groups.
We observed that all patients with significant fibrosis
and infection by genotype 1 who had drug dose reduction
did not achieve sustained virologic response, in contrast
to those infected by genotype 3. When analyzing patients
with non-significant fibrosis (F0, F1 and F2) who had
reduced drug doses, no difference was observed in the
sustained virologic response between genotypes 1 and 3.
Patients with genotype 3 and non-significant fibrosis had
a worse response to dose reduction than those with F3
and F4 stages.
Discussion
Overall, our population of non-responders is similar to
those of other studies and to the standard population of
patients infected by HCV in our country. There was
homogeneity regarding demographic, epidemiologic and
biochemical characteristics among patients infected by
genotypes 1 and 3, except for those who had significant
fibrosis (grades 3 and 4 on the Metavir fibrosis score),
whose percentage was proportionally higher for genotype
3 than genotype 1 (45% versus 37,8%).This was also seen
in other Brazilian studies [4,7]. We observed a higher per-
centage of IVDU among those infected by genotype 3
(32%) and a higher percentage of cirrhosis carriers (20%),
which could reduce the SVR rates.
It is known that patients who have relapses after the
standard IFN treatment, whether combined or not with
Table 1: Characteristics of the patient's population according to the genotypes (N = 130)
Characteristics All Genotype 1 Genotype 3
(N = 130) (N = 90) (N = 40)
Men n (%) 94 (72) 63 (70) 31 (77)
Race
Caucasian n (%) 117 (90) 79 (87) 38 (95)
Age median, years 48 46.5 49
Alcohol abuse present, n (%) 22 (17) 15 (16) 7 (17)
Possible acquisition route n (%)
IVDU 28 (21) 15 (16) 13 (32)
Parenteral 44 (33) 33 (36) 11 (27)
Parenteral and IVDU 5 (4) 3 (3) 2 (5)
Unknown 53 (40) 39 (43) 14 (35)
Leukocytes (× 104 cells/L) 6.35 6.35 5.94
median [interval] [2.7; 19] [2.7; 19] [3.9; 13]
Neutrophilis (× 106 cells/L) 3.38 3.28 5.94
median [interval] [0.33; 9.44] [0.33; 7.8] [0.8; 9.44]
Hemoglobin (mg/dL) 15.3 15.5 13.5
median [interval] [2.7; 19] [2.7; 19] [3.9; 13]
Platelets (× 103/mm3) 194 184 200
median [interval] [80; 345] [83; 345] [80; 275]
q ALT* 1.85 1.85 2.1
median [interval] [0.7; 9.3] [0.7; 5.1] [0.9; 9.3]
qALT* = U/NUL
Figure 1 Early virologic response (EVR) and sustained virologic 
response (SVR) in patients retreated with PEG-IFN alpha 2b plus 
RBV according to the HCV genotypes (n = 104).
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RBV, respond better to the retreatment with PEG-IFN
plus RBV than those not responding to the same regimes.
Krawitt et al. observed 55% of SVR in 66 relapsing
patients when retreated with PEG-IFN alpha 2b (100-150
μg/week) plus RBV (1,000 mg/day) against 20% of SVR in
116 previous non-responder patients treated with the
same regime [6]. They also observed SVR in 53% of the
relapsing patients infected by genotype 1 and in 59% of
the relapsing patients infected by genotypes 2/3. There-
fore, there was no significant difference in this group of
patients. This was not observed among the previous non-
responders when retreated. Of these, only 17% of patients
infected by genotype 1 presented SVR, as compared to
57% of the infected by the genotypes 2/3. Therefore, gen-
otype influenced the SVR in previous non-responders.
Multicentric studies, sponsored by pharmaceutical com-
panies and conducted in Brazil by Parise et al. with PEG-
IFN alpha-2a plus RBV [4] and by Gonçales Jr et al., with
PEG-IFN alpha-2b plus RBV [7], in patients who were
non-responders to IFN/RBV, found higher SVR percent-
ages (24-38%) when compared to the international stud-
ies. Sherman et al. found a SVR percentage of 23% among
the non-responders against a SVR of 41% among relaps-
ing patients after retreatment with PEG-IFN alpha-2a
and ribavirin [9]. In the present study, with real life
patients treated outside clinical trials, we found by inten-
tion-to-treat (ITT) analysis 22.2% (20/90) of SVR in the
patients infected by genotype 1 and 40% of SVR among
the infected by genotype 3. By per protocol analysis the
SVR also was lower in patients infected by genotype 3
(20/79, 25.3%) compared to 40% (16/40) of SVR in
patients infected by genotype 3. Because patients in this
study received all injections of PEG-IFN at a specialized
center we should expect better rates of SVR than those
treated in their homes. Again, the Brazilian patients who
were non-responders to previous treatment with IFN
plus RBV, when retreated, obtained good SVR rates, par-
ticularly those infected by the HCV genotype 1. The
lower SVR rate observed in our Brazilian patients,
infected by genotype 3, when compared to that observed
by Krawitt et al. (57%) may be associated with the type of
patient included by us, as 45% of them showed significant
fibrosis. Additionally, Krawitt et al., in contrast to the
present study, did not include non-responders to the IFN
monotherapy in their retreatment group.
Two large international studies, HALT-C and EPIC3,
that retreated with PEG-IFN α-2a/α-2b plus RBV HCV
patients who were non-responders or relapsers to previ-
ous treatment with interferon plus RBV, obtained 18% of
SVR for non-responders [5,8] and 43% of SVR for relaps-
ers [8]. The retreatment results for EPIC3 were better in
relapsers than in non-responders and, mainly, in those
who received IFN plus RBV previously as compared to
those who received PEG-IFN plus RBV. In EPIC3, the
early virologic response (week 12) was an important pre-
dictor of SVR, as 56% of the patients with undetectable
HCV-RNA obtained SVR, while no individual with
decrease ≤ 2log10  in the serum HCV-RNA had SVR.
Table 2: Early virologic (EVR) and sustained virologic response (SRV) according to the genotype and population 
characteristics.
Characteristics EVR Genotype 1 EVR Genotype 3 P value SVR Genotype 1 SVR Genotype 3 P value
Sex
Men 23% (13/5) 65% (13/20) 0.9917 27% (17/62) 32% (10/3) 0.7612
Women 30% (7/23) 83% (5/6) 22% (6/27) 33% (3/9)
Race Caucasian 28% (19/70) 60% (14/23) 0.7502 29% (14/47) 31% (12/38) 0.3662
Age
< 40 years 33% (3/9) 100% (4/4) 0.4856 40% (4/10) 50% (3/6) 0.2694
> 40 years 28% (19/67) 59% (13/22) 24% (18/75) 29% (10/34)
Alcohol abuse
Yes 22% (5/22) 20% (1/5) 0.1798 29% (8/27) 12% (1/8) 1.1
No 27% (15/55) 755 (15/20) 36% (15/41) 36% (12/33)
Exposure n (%)
IVDU 37% (6/16) 55% (5/9) 25% (4/16) 30% (4/13)
Parenteral 29% (8/27) 50% (3/6) 0.7038 25% (8/32) 36% (4/11) 1.073
Parenteral/IVDU 0% (0/3) 0% (0/1) 0.6794 0% (0/3) 25% (1/4) 1.053
Unknown 18% (6/32) 88% (8/9) 25% (4/16) 38% (5/13)
p value < 0.005 = significantGonçales et al. BMC Infectious Diseases 2010, 10:212
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Patients who had a decrease of at least 2 log10 in the viral
load obtained SVR of 12%. In our study, 65% of the
patients with HCV-genotype 1, with EVR, had SVR. Of
the patients infected by HCV-genotype 3, 56% had SVR.
It is important to note the poor liver profile of these
patients (45% presented F3/F4). The negative predictive
value was 88-89% showing the usefulness of carrying out
the HCV-RNA testing at week 12 in the retreatment
cases. With regard to week 4, there are no clear predic-
tiveness rules for patients on retreatment. Regarding the
dose reduction of medications throughout the treatment,
variations were observed in the SVR obtained for each
genotype. The lower SVR percentage (17%) was found in
the patients who had their PEG-IFN doses reduced. It is
important to point out, however, that the total sample
encompassed only 17 patients who had this medication
reduced. In the multivariate analysis, there was no statis-
tically significant difference in the SVR observed among
patients with or without the reduction of medications,
regardless of whether ribavirin or PEG-IFN was reduced.
It is probable that if the sample were more powerful it
would be possible to obtain a more reliable value for the
outcome of reducing pegylated interferon doses during
the treatment. Recent studies have shown that the fibrosis
grade is one of the primary predictors of worse therapeu-
tic response [5,8]. When comparing the liver fibrosis
grade with the SVR rate we did not find statistically sig-
nificant differences between the groups of patients. In the
initial stages of liver fibrosis, as evaluated by the META-
VIR score (F0, F1, F2), 24% of the patients with genotype
1 obtained SVR against 25% with genotype 3, which was
not significant. In advanced grades of fibrosis (F3, F4),
30% of SVR was observed in the group infected by HCV-
genotype 1 against 35% in the group infected by HCV-
genotype 3. In fact, in our study, the fibrosis grade itself
did not appear to affect the SVR. Perhaps this may be due
to a relatively small sample size of advanced fibrotics
enrolled. However, when analyzing the reduction of doses
of drugs, it was observed that none of the patients
infected with HCV genotype 1 who had significant fibro-
sis and reduction of drug had a sustained virological
response. In EPIC3, SVR predictors included: infection
by genotypes 2/3, presence of fibrosis F2/F3, viral load ≤
600,000 UI/ml, previous treatment with IFN monother-
apy and patients relapsing after the first treatment [8].
The results of our study confirmed that the response per-
centage was good for Brazilian patients infected by HCV
who were non-responders to the previous treatment with
IFN plus RBV when retreated in real life with PEG-IFN
plus RBV.
Conclusions
Our patients, retreated at assisted interferon application
hubs, had good virologic response rates. In the present
study, intention-to-treat (ITT) analysis showed an SVR of
22.2% (20/90) in those patients infected by genotype 1
and 40% (16/40) among those infected by genotype 3.By
per-protocol-analysis the SVR was also lower in patients
infected by genotype 1 (20/79, 25.3%) compared to 40%
(16/40) of SVR in patients infected by genotype 3.
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